California doctor sued for ‘wrongful death' after shipping abortion drugs interstate in legal first
Jerry Rodriguez filed a wrongful death lawsuit against Remy Coeytaux, after the doctor sent the abortion-inducing drugs across state lines in order to 'murder his unborn son,' Rodriguez claimed.
It appears to be the first time an interstate lawsuit for wrongful death over an abortion has been filed, according to The Washington Post.
In Texas, a person who assists a pregnant woman in obtaining a self-managed abortion commits the crime of murder and can be sued for wrongful death, the lawsuit, filed in Texas federal court and obtained by The Independent, states. The woman herself cannot be prosecuted.
The suit adds it is also a state jail felony for anyone other than a Texas-licensed physician to provide an abortion-inducing drug for the purpose of inducing an abortion.
'In violation of these and many other laws, defendant Remy Coeytaux mailed abortion-inducing drugs into Texas that were used to murder Jerry Rodriguez's unborn child,' the complaint reads.
Rodriguez is suing Coeytaux for $75,000 over what he claims is wrongful death. He's also seeking an injunction to stop the doctor from distributing abortion-inducing drugs in violation of state or federal law.
The injunction, the suit states, is being sought 'on behalf of a class of all current and future fathers of unborn children in the United States.'
But such state legislation clashes with that of California, which retains a so-called 'Shield Law' to protect medical professionals such as Coeytaux. The law provides that 'California will not deliver a person accused or charged with committing a crime related to abortion/gender-affirming care over to law enforcement officials.'
This includes situations where a California-licensed pharmacist dispenses an abortion-inducing drug mifepristone to a patient in a state with abortion-restrictive laws.
According to Rodriguez's suit, he began dating his girlfriend in June 2024, while she was separated from her husband, but not yet divorced. The Independent has chosen not to name the woman, due to privacy reasons and because she is not a defendant in the lawsuit.
The suit alleges that the woman's husband, Adam Garza, twice ordered the abortion medication from Coeytaux after she became pregnant by Rodriguez 'with the intent of using them to murder Mr. Rodriguez's unborn child,' and 'pressured her' to take the pills.
A Venmo receipt confirming Garza's purchase of the drugs from Coeytaux was included in the lawsuit, with a reference of ''Aed axes' – allegedly a homonym for 'Aid Access,' an organization that ships abortion-inducing drugs into jurisdictions where abortion is not legal.
'Defendant Coeytaux caused the death of Mr. Rodriguez's unborn child through his wrongful acts,' the lawsuit states.
'Although [the woman] cannot be charged with murder for her role in killing her unborn child, her immunity does not shield Coeytaux from liability for aiding or abetting or directly participating in the murder.'
'Mr. Rodriguez seeks this injunction on behalf of a class of all current and future fathers of unborn children in the United States.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Guardian
an hour ago
- The Guardian
Sales of Novo Nordisk's diabetes drugs including Ozempic slow sharply
Sales of Novo Nordisk's injectable diabetes drugs including Ozempic have slowed sharply amid fierce competition and the threat of US tariffs, prompting it to cut costs and sharpen its commercial focus. The Danish drugmaker, whose booming sales of GLP-1 diabetes and obesity drugs in recent years had turned it into Europe's most valuable company, has lost nearly $100bn (£75bn) in market value since cutting its full-year sales forecast last week, when its share price slid 30% in its worst week in more than two decades. It fell a further 3% on Wednesday. On Wednesday, Novo Nordisk said sales of medications such as Ozempic – which mimic the GLP-1 gut hormone that regulates blood sugar levels and appetite – grew by 8% in the first half of the year, down from 21% last year. Sales of obesity drugs including Wegovy increased by 56%, taking total sales 16% higher to 155bn Danish kroner (£18bn). Profit before tax climbed by 24% to 70.8bn kroner. The company has lost market share to its US rival Eli Lilly's Mounjaro, which studies have shown to be more effective, as well as cheaper versions made by generic drugmakers. It has also been hit by 'compounding' in the US, where pharmacies make up medications from ingredients, even though the US regulator declared an end to the practice recently. Novo Nordisk's outgoing chief executive, Lars Fruergaard Jørgensen, said that the copycat market had 'equal size to our business' and that compounded versions of Wegovy were sold at a 'much lower price point'. Its finance chief, Karsten Munk Knudsen, said the company was pursuing various strategies, including lawsuits against compounding pharmacies and expanding its US direct-to-consumer platform, NovoCare, launched in March. The company might also pursue 'cash sales' directly to patients elsewhere. Jørgensen said Novo Nordisk was taking measures to 'sharpen our commercial execution further, and ensure efficiencies in our cost base while continuing to invest in future growth'. He said it would probably not be able to avoid layoffs, but that no decision had been made. He said it would be up to Maziar Mike Doustdar, who takes over as CEO on Thursday, to make such a decision. The company is now expecting sales growth of between 8% and 14% at constant exchange rates in 2025, down sharply from its previous estimate of 13% to 21%. Novo Nordisk also disclosed that it had ditched several weight-loss drugs in development, including one that has just completed an intermediate (phase II) clinical study, 'due to portfolio considerations'. The company faces a class action lawsuit in the US from investors, who claim that it misled them with optimistic growth forecasts in the lucrative weight loss market. The UBS analyst Matthew Weston said: 'We expect GLP-1 compounders to remain in the US, which limits cash-pay uptake and leaves an uncertain outlook for US Wegovy. Sign up to Business Today Get set for the working day – we'll point you to all the business news and analysis you need every morning after newsletter promotion 'President Trump's proposal to reimburse GLP-1 obesity in Medicare could add significant volume uplift, but most-favoured-nation demands to offer US cash sales at European prices could significantly reduce value.' Derren Nathan, the head of equity research at Hargreaves Lansdown, said: 'Tariffs and drug pricing policy are another threat Mike Doustdar will need to tackle head-on if one of Denmark's greatest success stories is to regain its crown as Europe's most valuable company. 'The 15% blanket rate on EU imports is not necessarily the end of the story as Donald Trump dangles the prospect of levies of up to 250% on pharmaceutical imports under a separate section 232 investigation.'
Times
an hour ago
- Times
Nearly half of doctors in Scotland witness care failings every week
Almost half of Scotland's doctors witness patient safety being compromised at least once a week, the medical regulator has said. The General Medical Council (GMC) found that 46 per cent of clinicians north of the border see care failings weekly, a higher proportion than elsewhere in the UK. Backlogs in accident and emergency departments, resulting in thousands of patients stuck on trolleys for hours queueing for beds, are thought to be one of the issues driving potential errors. Dr Iain Kennedy, chair of the British Medical Association in Scotland, described the findings as extremely alarming and said that the doctor workforce was operating at 'dangerously low levels'. The latest GMC survey showed a reduction in the number of doctors noting safety incidents weekly in England, Wales and Northern Ireland since 2023 — but an increase in Scotland. Its report, published on Thursday, said: 'In 2024, Scotland fared worse than the UK average in some areas — most notably on patient safety.' Dr Sandesh Gulhane, a GP and health spokesman for the Scottish Conservative Party, said emergency measures such as treating patients in corridors had become routine. He added that staff did not always have access to the life-saving equipment they needed and were more prone to making mistakes because of the pressures, compromising patient safety. 'Nearly two decades of chronic SNP mismanagement has brought our health service to its knees and patients are being put in danger as a result,' he said. The GMC, which serves to protect the public by ensuring high standards of medical training and practice UK-wide, analyses staff experiences on the frontline of the NHS every year. Last year 450 doctors in Scotland participated in the survey and a total of 4,700 were involved UK-wide. Asked if they found it difficult to provide sufficient care for a patient at least once a week, 42 per cent in Scotland said they did, compared with 39 per cent in England. Across the UK 40 per cent of doctors said they had witnessed patient safety or care being compromised at least once a week — 6 per cent less than in Scotland. Clinicians in Scotland also felt less empowered to bring about improvements with 40 per cent saying they could not influence change, compared with 35 per cent for the UK as a whole. Just 37 per cent felt supported by non-medical managers, while the figure was 42 per cent UK-wide. Kennedy said: 'BMA Scotland has been warning for some time that doctor workforce provision in Scotland's NHS is at dangerously low levels, which leads to patients having to wait far too long for treatment and doctors who are stretched to breaking point.' 'There is a major question over how waiting lists can be tackled and how any extra capacity in the health service can be delivered when there are not enough consultants to keep up with current demand and while GP practices are struggling to deliver the services their patients deserve. This is a result of the devastating impact of years of underinvestment which has left many GP practices unable to take on more GPs due to a lack of funding.' He added that it was alarming to see from the survey that 22 per cent of doctors in Scotland were likely to consider moving overseas. This was compared with 27 per cent in the UK as a whole. Dame Jackie Baillie, a health spokeswoman for Scottish Labour, said: 'There are exceptional staff in our NHS who work diligently to care for patients. They are the ones raising the alarm about patient safety, so this is a wake-up call for the Scottish government who are far too complacent.' Fiona Hunter, vice-president of the Royal College of Emergency Medicine Scotland, said: 'This survey is a barometer of how clinicians are feeling, and what they are experiencing at work — and it reveals a saddening and shocking reality. She said the failures were not the fault of the clinicians. 'They are battling in a struggling system, and despite their best efforts, sadly some patients are being put at risk,' she said. 'The Scottish government must listen to the voices of those in this report — and heed the alarm bells so clearly sounding. Our members, their colleagues, and our patients across the country deserve so much better.' A Scottish government spokesman said: 'Patient safety is paramount and we will ensure any concerns raised by the GMC are fully considered and addressed. 'We want doctors to feel their voices are heard — our Future Medical Workforce project will collect direct feedback from physicians in the coming months to help shape future reforms in training and recruitment and ensure being a doctor is a sustainable and fulfilling career path.'
The Independent
2 hours ago
- The Independent
Warning issued as man dies after taking ‘addictive' supplement
A Washington family is raising awareness about the dangers of kratom after their son, Jordan McKibban, died in 2022 from using the supplement. McKibban's autopsy revealed his death was caused by mitragynine, a compound found in kratom, which he had mixed with lemonade. Kratom, an "all-natural" supplement derived from a Southeast Asian plant, is legally available but the US Food and Drug Administration (FDA) has labelled it a "drug of concern" due to unproven safety and efficacy. Concerns are growing over 7-hydroxymitragynine, a more potent kratom offshoot, which the FDA has recommended classifying as an illicit substance due to its opioid-like effects. US Secretary of Health and Human Services Robert F Kennedy Jr has announced plans to crack down on kratom, particularly the more addictive offshoot, while Dr Robert Levy warned consumers that "all-natural" does not equate to safety.
